26 64

Cited 0 times in

MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria

Authors
 Mohamed A Yassin  ;  Ali Taher  ;  Vikram Mathews  ;  Hsin-An Hou  ;  Tahir Shamsi  ;  Tülin Firatli Tuğlular  ;  Zhijian Xiao  ;  Soo-Jeong Kim  ;  Wu Depei  ;  Junmin Li  ;  Gerd Rippin  ;  Islam Sadek  ;  Asif Siddiqui  ;  Raymond S Wong 
Citation
 CANCER MEDICINE, Vol.9(13) : 4512-4526, 2020-07 
Journal Title
CANCER MEDICINE
Issue Date
2020-07
MeSH
Aged ; Algeria / epidemiology ; Asia / epidemiology ; Bone Marrow / pathology ; Disease Progression ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Myeloproliferative Disorders / diagnosis ; Myeloproliferative Disorders / drug therapy ; Myeloproliferative Disorders / epidemiology* ; Patient Acceptance of Health Care / statistics & numerical data ; Polycythemia Vera / drug therapy ; Polycythemia Vera / epidemiology ; Prevalence ; Primary Myelofibrosis / drug therapy ; Primary Myelofibrosis / epidemiology ; Prospective Studies ; Quality of Life ; Registries / statistics & numerical data* ; Splenomegaly / diagnosis ; Symptom Assessment ; Thrombocythemia, Essential / drug therapy ; Thrombocythemia, Essential / epidemiology ; Turkey / epidemiology
Keywords
epidemiology ; myeloproliferative disorders ; neoplasms ; quality of life
Abstract
Philadelphia chromosome-negative (Ph-) myeloproliferative neoplasms (MPNs) are a heterogeneous group of clonal disorders of the bone marrow, and are associated with a high disease burden, reduced quality of life (QOL), and shortened survival. This multinational, multicenter, non-interventional registry "MERGE" was initiated with an objective to collect data on the epidemiological indices of classical Ph-MPNs, existing treatment patterns, and impact of MPNs on health-related QOL in various countries/regions in Asia, including the Middle East, Turkey, and Algeria. Of the 884 eligible patients with MPNs, 169 had myelofibrosis (MF), 301 had polycythemia vera (PV), 373 had essential thrombocythemia (ET), and 41 had unclassified MPNs. The median age was 58 years (range, 47-66 years), and 50% of patients were males. The prevalence and incidence of MPNs were estimated to be 57-81 and 12-15 per 100 000 hospital patients per year over the last 4 years, respectively, in these countries. Total symptom score (mean [standard deviation; SD]) at baseline was highest in patients with MF (23.5 [17.47]) compared with patients with ET (14.6 [14.26]) and PV (16.6 [14.84]). Patients with ET had a lower mean (SD) number of inpatient visits (0.9 [0.77] days), and patients with MF had more outpatient visits (5.2 [3.17] days) on an average, compared with the entire MPN group. The study showed that patients with MPNs have a severe disease burden and reduced QOL. A discordance between physician and patient perception of symptom assessment was observed in this study (International clinical trials registry ID: CTRI/2014/05/004598).
Files in This Item:
T9992020270.pdf Download
DOI
10.1002/cam4.3004
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Soo Jeong(김수정) ORCID logo https://orcid.org/0000-0001-8859-3573
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/190048
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links